Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS54
PHASE 3 / 2-326
RECRUITING38
READOUTS ≤12 MONTHS12
READOUT SLIPPED >6 MO19%
Delay Index: of 32 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Suzhou Suncadia Biopharmaceuticals Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SHR-1701、CAPOX NCT04950322 |
P3 | Active, not recruiting | Gastric or Gastroesophageal Junction Cancer | 737 | 2024-05-20 |
| NCT07028268 NCT07028268 |
P2 | Recruiting | For Prevention of Bone Events in Patients With Bone Metastases From Solid Tumors | 210 | 2025-12 |
| SHR-8068;Adebrelimab;Oxaliplatin;Capecitabine Tablets;Paclitaxel Injection;Cisplatin Injection NCT06247956 |
P2 | Active, not recruiting | Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma | 153 | 2025-12-30 (+11 mo) |
| SHR-1826 NCT06703177 |
P1/2 | Recruiting | Advanced Solid Tumors | 876 | 2026-01-01 |
| SHR-A1811 NCT06199973 |
P3 | Active, not recruiting | Advanced Colorectal Cancer | 130 | 2026-04 |
| SHR-A1921 NCT06394492 |
P3 | Recruiting | Ovarian Cancer | 440 | 2026-05-31 |
| SHR-1314 injection NCT06640257 |
P3 | Active, not recruiting | Psoriatic Arthritis | 208 | 2026-06-05 (+1 mo) |
| SHR-1314 NCT06833307 |
P3 | Not yet recruiting | Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis | 90 | 2026-07 |
| Adebrelimab Injection NCT07110571 |
P2 | Recruiting | Gastric Cancer; Gastroesophageal-junction Cancer | 200 | 2026-08 |
| SHR-A1811 NCT06859775 |
P1/2 | Recruiting | Recurrent or Metastatic Cervical Cancer | 100 | 2026-10 |
| SHR-8068 NCT06618664 |
P3 | Recruiting | Advanced Hepatocellular Carcinoma | 590 | 2026-10 (+6 mo) |
| SHR-1681 NCT06737731 |
P1/2 | Recruiting | Malignant Solid Tumors | 300 | 2026-11 |
| SHR-A2009 monotherapy NCT06671379 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 498 | 2026-12 |
| SHR-1826;Adebrelimab;SHR-8068;Bevacizumab NCT06844474 |
P2 | Recruiting | NSCLC | 300 | 2026-12 (+3 mo) |
| SHR-A1811 NCT06840002 |
P1/2 | Recruiting | Ovarian Cancer | 150 | 2026-12 (+7 mo) |
| SHR-8068 NCT06465563 |
P2 | Active, not recruiting | Biliary Tract Cancer | 93 | 2026-12-30 |
| SHR-4375 Injection NCT07298772 |
P1/2 | Recruiting | Advanced Solid Tumor | 198 | 2027-01 |
| SHR-A1912 Injection NCT06929624 |
P3 | Active, not recruiting | Diffuse Large B-cell Lymphoma | 282 | 2027-03 |
| SHR-A2102 NCT07059221 |
P1/2 | Recruiting | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | 210 | 2027-03 (+12 mo) |
| SHR-9839(sc) For Injection NCT07229638 |
P1/2 | Recruiting | Solid Tumor | 70 | 2027-04 (-14 mo) |
| SHR-4375 NCT06764628 |
P1/2 | Recruiting | Solid Tumors | 208 | 2027-05 |
| SHR-8068 Injection NCT07682272 |
P2 | Not yet recruiting | Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk | 120 | 2027-07 |
| Almonertinib combined with SHR-1701 NCT05503888 |
P1/2 | Not yet recruiting | Relapsed or Advanced Non-small Cell Lung Cancer | 160 | 2027-07-30 |
| SHR-9839(sc) for Injection NCT07751341 |
P2 | Recruiting | Advanced Esophageal Squamous Cell Carcinoma | 84 | 2027-12 |
| SHR-A2102 for Injection NCT07418749 |
P3 | Recruiting | Recurrent Cervical Cancer; Metastatic Cervical Cancer | 398 | 2027-12 |
| SHR-1826 NCT06754930 |
P1/2 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 400 | 2027-12 |
| SHR-A1811 and SHR-1701 NCT05671822 |
P2 | Recruiting | HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | 258 | 2027-12 (+16 mo) |
| SHR-3276 NCT06643754 |
P1/2 | Recruiting | Advanced Solid Tumors | 115 | 2027-12-30 |
| SHR-A2102 and Adebrelimab NCT07393542 |
P3 | Recruiting | Locally Advanced or Metastatic Urothelial Carcinoma | 453 | 2028-01-31 |
| SHR-1314 Injection NCT06860750 |
P3 | Recruiting | Active Non-radiographic Axial Spondyloarthritis | 380 | 2028-02 (+10 mo) |
| SHR-A1811 for Injection NCT07111832 |
P3 | Recruiting | PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer | 400 | 2028-03 |
| SHR-A1811 NCT06778031 |
P2 | Recruiting | HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer | 54 | 2028-06 |
| Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection NCT07704645 |
P2 | Not yet recruiting | Resectable Non-small Cell Lung Cancer | 180 | 2028-06 |
| SHR-1826 NCT07489716 |
P2 | Recruiting | Non-Small Cell Lung Cancer | 90 | 2028-08 |
| SHR-4298 Injection NCT07229612 |
P1/2 | Recruiting | Malignant Solid Tumors | 200 | 2028-11 |
| SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin NCT07028281 |
P2 | Recruiting | Malignant Solid Tumors | 120 | 2028-12 |
| adebrelimab + SHR-A2009 NCT07863167 |
P2 | Recruiting | Non-small Cell Lung Cancer | 660 | 2028-12-30 |
| SHR-A2009 + bevacizumab NCT07895992 |
P3 | Not yet recruiting | Non-squamous Non-small Cell Lung Cancer | 490 | 2028-12-30 |
| SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab NCT07676162 |
P3 | Recruiting | Advanced Colorectal Cancer | 300 | 2029-09 |
| NiBladder 2 NCT07726992 |
P3 | Recruiting | Papillary-Only Non-muscle-invasive Bladder Cancer | 750 | 2029-12 |
| SHR-8068 Injection NCT07229625 |
P3 | Recruiting | Advanced Biliary Tract Cancer | 604 | 2029-12 |
| trastuzumab NCT07779538 |
P3 | Recruiting | Ovarian Cancer | 420 | 2030-02-28 |
| SHR-1501 for Injection NCT07424287 |
P3 | Recruiting | NMIBC | 236 | 2030-06 |
| SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or Fluorouracil Injection NCT07118527 |
P3 | Recruiting | Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma | 600 | 2030-10 |
| SHR-A1904 for Injection NCT07450976 |
P2 | Recruiting | Biliary Tract Cancer | 151 | 2030-12 |
| SHR-8068;Adebrelimab ;Bevacizumab NCT07239596 |
P1/2 | Recruiting | Advanced Renal Cell Carcinoma | 92 | 2030-12 |
| Trastuzumab Rezetecan for Injection NCT07679360 |
P3 | Recruiting | Triple Negative Breast Cancer | 1000 | 2030-12 |
| SHR-8068,adebelizumab and platinum-based chemotherapy NCT07170995 |
P3 | Recruiting | Advanced or Metastatic Non-small Cell Lung Cancer | 460 | 2030-12 |
| SHR-A1811 Injection NCT07896005 |
P3 | Not yet recruiting | Non Small Cell Lung Cancer | 436 | 2031-02 |
| SHR-8068 + Adebrelimab + Bevacizumab NCT07691762 |
P3 | Not yet recruiting | Hepatocellular Carcinoma | 690 | 2031-09 |
| SHR-8068 Injection NCT07071714 |
P2 | Active, not recruiting | Colorectal Cancer | 103 | 2031-10 |
| SHR-A2102 NCT06879145 |
P2/3 | Recruiting | Muscular Invasive Bladder Cancer (MIBC) | 740 | 2031-12 |
| Adebrelimab in combination with SHR-8068 and chemotherapy NCT07454720 |
P2/3 | Recruiting | Locally Advanced Resectable Rectal Cancer | 165 | 2032-11 |
| SHR-A2009 ; Aumolertinib NCT07183189 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 582 | 2032-11 |